# A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer

> clinical trial · VERIFIED · 2026-08-18

Status: NOT_YET_RECRUITING · Sponsor: First Affiliated Hospital of Fujian Medical University · Condition: ALK-positive Non Small Cell Lung Cancer

- Company: First Affiliated Hospital of Fujian Medical University
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07771764

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.